
Study data show a significant benefit of neoadjuvant immunotherapy in HR-positive early breast cancer for the first time
Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress